Pfizer taps Sanford-Burnham for obesity, diabetes R&D
This article was originally published in Scrip
Executive Summary
Pfizer will access the drug screening and target validating capabilities of the Sanford-Burnham Medical Research Institute in Orlando, Florida to find new therapeutic targets and drug candidates for the prevention and treatment of obesity and diabetes.